Regor Therapeutics
Innovative drug candidates targeting metabolism, oncology, and autoimmunity with potential blockbuster therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | $50.0m | Late VC | |
| Total Funding | 000k | ||
Related Content
Regor Therapeutics Group focuses on developing innovative drug candidates to address significant unmet medical needs in the fields of metabolism, oncology, and autoimmunity. The company operates in the biopharmaceutical sector, leveraging its Computer Accelerated Rational Discovery platform to expedite the drug discovery process. Regor's clinical pipeline includes promising candidates such as RGT-075, a once-daily oral small molecule full agonist of GLP-1R, and RGT-419B, a next-generation CDK4 inhibitor showing efficacy in refractory ER HER2 breast cancer. The company collaborates with global leaders like Lilly to enhance its research and development capabilities. Regor primarily serves patients with metabolic disorders, various cancers, and autoimmune diseases, aiming to bring breakthrough therapies to market. The business model revolves around research and development, clinical trials, and strategic partnerships, generating revenue through licensing agreements and potential future drug sales.
Keywords: biopharmaceutical, drug discovery, metabolism, oncology, autoimmunity, GLP-1R agonist, CDK4 inhibitor, clinical trials, strategic partnerships, innovative therapies.